Celon PharmaWAR:CLN -0.60%49 OCF Yield % is 2.85 as of Jul. 01, 2026, which is 102% above its 10-year median of 1.41. GuruFocus rates WAR:CLN with a GF Score™ of 49/100 and a GF Value™ of zł22.86 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,002 Drug Manufacturers companies, Celon Pharma ranks worse than 53.99% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Celon Pharma OCF Yield % Related Terms
Celon Pharma OCF Yield % Historical Data
* Premium members only.
The historical data trend for Celon Pharma's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:CLN vs ZTS, UTHR, VTRS: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celon Pharma (WAR:CLN) has a OCF Yield % of 2.85 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Celon Pharma and its competitors. This is 102% above median its historical median of 1.41. According to the industry distribution chart, Celon Pharma ranks #541 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Celon Pharma's OCF Yield % too high?
Celon Pharma's current OCF Yield % of 2.85 is 102% above median its 10-year median of 1.41. The Drug Manufacturers industry median OCF Yield % is 3.61. Celon Pharma's value of 2.85 is 20.9% below this industry median. Based on the distribution chart, Celon Pharma ranks #541 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Celon Pharma has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #541 out of 1002 companies for OCF Yield %. This places Celon Pharma in the lower half of its industry. The industry median OCF Yield % is 3.61. Celon Pharma's value of 2.85 is 20.9% below this benchmark. While the company's 10-year median is 1.41 vs. the industry median of 3.61, Celon Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celon Pharma's current OCF Yield % of 2.85 is 20.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current OCF Yield % is 2.85, which is 102% above median its own 10-year median of 1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł22.86, compared to a current price of zł19.72 — trading 13.7% below its estimated fair value. The current OCF Yield % is 2.85, which is 102% above median its 10-year median of 1.41 and 20.9% below the Drug Manufacturers industry median of 3.61. Celon Pharma's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current OCF Yield % is 2.85 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (WAR:CLN) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł19.72 is trading 13.7% below its estimated GF Value™ of zł22.86.
GuruFocus considers Celon Pharma to be Modestly Undervalued.
Key valuation signals for WAR:CLN:
OCF Yield %: 2.85 (102% above median its 10-year median of 1.41)
GF Value™: zł22.86 vs. price of zł19.72 (13.7% below fair value)
Industry Position: 20.9% below the Drug Manufacturers median (#541 of 1002)
No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
49GF Score
Get the complete analysis for WAR:CLN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:CLN has been successfully added to your 
